Evidence map›Paper›PMID 34617412›Full record

ArticleESC heart failure2021

Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart.

Shingo Takahara, Shubham Soni, Kiran Phaterpekar, Ty T Kim, Zaid H Maayah, Jody L Levasseur, Heidi L Silver, Darren H Freed, Mourad Ferdaoussi, Jason R B Dyck

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Energy metabolism in health and diseases.Signal transduction and targeted therapy · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Ketones and the cardiovascular system.Nature cardiovascular research · 2023
    Review
  20. Metabolic Changes in Cardiac Aging.Reviews in cardiovascular medicine · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Shingo TakaharaCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.ORCID 0000-0002-8363-293X
Shubham SoniCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.ORCID 0000-0003-3488-1208
Kiran PhaterpekarCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Ty T KimCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Zaid H MaayahCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Jody L LevasseurCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Heidi L SilverCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Darren H FreedDepartment of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Mourad FerdaoussiCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.
Jason R B DyckCardiovascular Research Centre, Department of Pediatrics, Faculty of Medicine and Dentistry, University of Alberta, 458 Heritage Medical Research Centre, Edmonton, Alberta, T6G 2S2, Canada.ORCID 0000-0002-7045-2884
University of Alberta · CA

Funding

CIHR
6 · The paper itself

Abstract

aimsRecent evidence has demonstrated that ketone bodies, particularly β-hydroxybutyrate (BHB), are beneficial to the failing heart due to their potential as an alternative energy substrate as well as their anti-inflammatory and anti-oxidative properties. Exogenous supplementation of ketones also helps prevent heart failure (HF) development in rodent models, but whether ketones can be used to treat HF remains unexplored. Herein, we investigated whether chronic supplementation of ketones is beneficial for the heart in a mouse model of established HF. METHODS AND

resultsTo elevate circulating ketone levels, we utilized (R)-3-hydroxybutyl-(R)-3-hydroxybutyrate [ketone ester (KE)]. C57Bl/6N male mice were subjected to transverse aortic constriction (TAC) surgery. After developing HF, mice were treated with either 20% KE or vehicle via drinking water for 2 weeks. In another cohort, mice 3-4 weeks post-TAC received acute intravenous infusions of BHB or saline for 1 h and their cardiac function was measured. 20% KE significantly elevated blood BHB in mice (P < 0.01) without inducing ketoacidosis or altering other metabolic parameters. Mice with overt HF (30-45% ejection fraction) treated with 20% KE displayed significantly elevated circulating ketone levels compared with vehicle-treated mice (P < 0.05). The significant cardiac dysfunction in mice with HF continued to worsen after 2 weeks of vehicle treatment, whereas this decline was absent in KE-treated mice (mean difference 4.7% ejection fraction; P < 0.01). KE treatment also alleviated TAC-induced cardiomyocyte hypertrophy (P < 0.05) and reduced the TAC-induced elevated cardiac periostin (P < 0.05), a marker of activated fibroblasts. Cardiac fibrosis was also significantly reduced with KE treatment in TAC mice (P < 0.01). In another cohort, acute BHB infusion significantly increased the cardiac output of mice with HF (P < 0.05), providing further support that ketone therapy can be used to treat HF.

conclusionsWe show that chronic treatment of exogenous ketones is of benefit to the failing heart and that chronic ketone elevation may be a therapeutic option for HF. Further investigations to elucidate the underlying mechanism(s) are warranted.

Indexed as

Heart FailureKetonesAnimalsDietary SupplementsHumansMaleMiceStroke VolumeVentricular Function, LeftKetonesHeart failureKetone esterβ-Hydroxybutyrate

Identifiers

PMID34617412
PMCPMC8712827
OpenAlexW3203351562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.